Elevation Pharmaceuticals Announces Positive Phase 2b Results for EP-101 for the Treatment of Chronic Obstructive ...

SAN DIEGO, May 16, 2012 /PRNewswire/ -- Elevation Pharmaceuticals, Inc., a pharmaceutical company focused on the development of new aerosol therapies for patients with respiratory diseases, announced today ...

Sunovion Announces Upcoming Availability of ZETONNA™ (ciclesonide) Nasal Aerosol, a Non-Aqueous, Dry Nasal Aerosol ...

Sunovion Pharmaceuticals Inc. today announced the upcoming availability of ZETONNA™ Nasal Aerosol, 74 mcg once-daily, for the treatment of allergic rhinitis , also known as hay fever or nasal allergies.

MS Drug Gilenya Positive Benefit-Risk Profile Following CHMP Review, Europe

According to Novartis, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has confirmed a positive benefit-risk profile for their once-a-day orally administered drug Gilenya (fingolimod). In agreement with the CHMP, the company has updated their E.U. product information after the Article 20 review the EMA announced in January 2012, in order to offer ...

Gilenya Successfully Treated Relapsing MS Patients For Up To 7 Years

At the 64th annual meeting of the American Academy of Neurology (AAN), Novartis will present new data that supports Gilenya's (fingolimod) efficacy and safety profile and introduce new data of its investigational compound BAF312 (siponimod), a selective modulator of the S1P receptor subtypes 1 and 5 (S1P1, -5R modulator) in its multiple sclerosis portfolio3. Gilenya (fingolimod) is the only oral ...